# Centers for Disease Control and Prevention Center for Preparedness and Response



# Treating Long COVID: Clinician Experience with Post-Acute COVID-19 Care

Clinician Outreach and Communication Activity (COCA) Webinar

Thursday, January 28, 2021

# **Continuing Education**

All continuing education for COCA Calls is issued online through the CDC Training & Continuing Education Online system at <a href="https://tceols.cdc.gov/">https://tceols.cdc.gov/</a>

Those who participate in today's COCA Call and wish to receive continuing education please complete the online evaluation by March 1, 2021, with the course code WC2922-012821. The access code is COCA012821. Those who will participate in the on-demand activity and wish to receive continuing education should complete the online evaluation between March 2, 2021 and March 2, 2023 and use course code WD2922-012821. The access code is COCA012821.

Continuing education certificates can be printed immediately upon completion of your online evaluation. A cumulative transcript of all CDC/ATSDR CEs obtained through the CDC Training & Continuing Education Online System will be maintained for each user.

# **Continuing Education Disclaimer**

- In compliance with continuing education requirements, CDC, our planners, our presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters.
- Planners have reviewed content to ensure there is no bias.
- The presentation will not include any discussion of the unlabeled use of a product or a product under investigational use.
- CDC did not accept commercial support for this continuing education activity.

# **Objectives**

- Identify signs and symptoms of long COVID which occur after the acute phase of SARS-CoV-2 infection.
- Identify potential multidisciplinary teams for patient care.
- Describe common challenges to post-acute COVID-19 care.
- Describe examples of patient-centered, interdisciplinary post-acute COVID-19 care.

# To Ask a Question

- All participants joining us today are in listen-only mode.
- Using the Webinar System
  - Click the "Q&A" button.
  - Type your question in the "Q&A" box.
  - Submit your question.
- The video recording of this COCA Call will be posted at <a href="https://emergency.cdc.gov/coca/calls/2021/callinfo\_012821.asp">https://emergency.cdc.gov/coca/calls/2021/callinfo\_012821.asp</a> and available to view on-demand a few hours after the call ends.
- If you are a patient, please refer your questions to your healthcare provider.
- For media questions, please contact CDC Media Relations at 404-639-3286, or send an email to media@cdc.gov.

# **Today's Presenters**

Alfonso C Hernandez-Romieu, MD, MPH LCDR, U.S. Public Health Service Late Sequelae Unit, Clinical Team COVID-19 Response Centers for Disease Control and Prevention



Jennifer Possick, MD
 Associate Professor, Section of Pulmonary, Critical Care and Sleep Medicine
 Department of Internal Medicine
 Yale University School of Medicine




Allison Navis, MD
 Assistant Professor, Division Neuro-Infectious Diseases
 Icahn School of Medicine at Mount Sinai
 Mount Sinai Health System



# Treating Long COVID: Clinician Experience with Post-Acute COVID-19 Care

Alfonso Hernandez-Romieu MD, MPH
Epidemic Intelligence Service
LCDR, United States Public Health Service
January 28, 2021
Clinician Outreach and Communication Activity
COCA Call



cdc.gov/coronavirus

# As reports of long-term COVID-19 symptoms emerged, the need for scientific research about **long COVID** has intensified.



'I Got COVID 9 Months Ago and Still Have Symptoms'

#### The New York Times

For Long-Haulers, Covid-19 Takes a Toll on Mind as Well as Body

"It makes you depressed, anxious that it's never going to go away."



The many strange long-term symptoms of Covid-19, explained

Long Covid "is a phenomenon that is really quite real and quite extensive," Anthony Fauci said.

By Lois Parshley | Dec 15, 2020, 4:20pm EST



PUZZLING, OFTEN DEBILITATING AFTER-EFFECTS PLAGUING COVID-19 "LONG-HAULERS"

Doctors are still searching for answers to why a portion of people who were diagnosed with COVID-19 are still suffering symptoms months later. Anderson Cooper reports.



# Coronavirus survivors plagued by long-term ailments

Symptoms include losing sense of smell, dry cough, fever and chronic fatigue



Long Covid: 'I thought I'd get over this no problem'

BBC News NI

## SCIENTIFIC AMERICAN.

LOCAL // HEATHER KNIGHT

S.F. Millennial was fit and healthy before COVID-19. He's a disabled 'long-hauler' now





SHORT WAVE

What's It Like To Be A COVID-19 'Long Hauler'

November 9, 2020 · 4:00 AM ET




PUBLIC HEALTH | OPINION

#### The Problem of 'Long Haul' COVID

More and more patients are dealing with major symptoms that linger for months

By Carolyn Barber on December 29, 2020

# Long COVID may overlap with other complications of acute COVID-19 illness making it **hard to define**.





<sup>\*</sup>Multisystem inflammatory disorder, Guillain-Barre, among others


<sup>\*\*</sup>Post-Intensive Care Syndrome

Long COVID often presents as reported persistent severe fatigue, headaches, and brain fog (mild subjective cognitive impairment) >4 weeks after acute illness and may be independent of acute illness severity.




# **Three quarters** of patients hospitalized with COVID-19 had at least one ongoing symptom 6 months after their acute illness.

Symptoms among 1,733 patients after hospitalization for COVID-19, China



# One in five patients not requiring supplemental oxygen during hospitalization had decreased lung function after 6 months.

Pulmonary function and 6-minute walk test distance results among COVID-19 hospitalized patients





LLN = lower limit of normal; DLCO = diffusion capacity for carbon monoxide

# Prolonged symptoms are common among patients with mild COVID-19 disease not requiring hospitalization.


- Survey of patients in a post-COVID 19 clinic in France<sup>1</sup> and telephone surveys in the Faroe islands<sup>2</sup> and Switzerland<sup>3</sup>
  - 35-54% of patients with mild acute COVID-19 had persistent symptoms after 2-4 months
  - 50-76% of patients reported new symptoms not present in their acute COVID-19 illness or symptoms that resolved and reappeared¹
  - 9% reported prolonged symptoms as severe<sup>2</sup>



<sup>2.</sup> Petersen et al., Clin Infect Dis. 2020

# More than one quarter of patients developed new neurological symptoms after their acute COVID-19 illness.

COVID-19 symptoms among 70 non-hospitalized patients, France



# **Key points**

- New or persistent symptoms (lasting >4-6 months) may occur among patients with COVID-19 regardless of acute episode severity.
- In addition to respiratory symptoms, patients may present with fatigue, sleeping difficulties, depression, anxiety, and neurological dysfunction.
- Baseline and serial comprehensive reviews of systems and physical exams may better document possible long COVID manifestations and improve management.
- There is still a lot we do not understand, and empathy toward patients experiencing long COVID is fundamental.

# CDC is involved in a multipronged approach to understand and characterize long COVID.

- Cohort studies
- Administrative data and chart reviews
- Patient surveys
- Clinician engagement
- Partnering with other agencies and organizations
- Public and clinical messaging



YOUR HEALTH

### Long-Term Effects of COVID-19

Updated Nov. 13, 2020

Print

https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects.html

HEALTHCARE WORKERS

### Late Sequelae of COVID-19

Updated Nov. 13, 2020

Print

https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/late-sequelae.html

### Resources

- CDC webpages on long COVID:
  - For the general public: <a href="https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects.html">https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects.html</a>
  - For clinicians: <a href="https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/late-sequelae.html">https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/late-sequelae.html</a>
- NIH Workshop on Post-Acute Sequelae of COVID-19
  - Day 1: <a href="https://videocast.nih.gov/watch=38878">https://videocast.nih.gov/watch=38878</a>
  - Day 2: <a href="https://videocast.nih.gov/watch=38879">https://videocast.nih.gov/watch=38879</a>



### References

- Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020 Aug 11;370:m3026.
- Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021 Jan 8:S0140-6736(20)32656-8.
- Salmon-Ceron D, Slama D, De Broucker T, et al. Clinical, virological and imaging profile in patients with prolonged forms of COVID-19: A cross-sectional study. J Infect. 2020 Dec 4:S0163-4453(20)30762-3.
- Petersen MS, Kristiansen MF, Hanusson KD, et al. Long COVID in the Faroe Islands a longitudinal study among non-hospitalized patients. Clin Infect Dis. 2020 Nov 30:ciaa1792.




# Thank you

CDC COVID-19 Healthcare Systems and Worker Safety Task Force
Healthcare Systems Coordination Unit
<a href="mailto:eocmcctfhome@cdc.gov">eocmcctfhome@cdc.gov</a>



## Disclaimer

The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC).





cdc.gov/coronavirus

# Treating Long-COVID: Clinician Experience with Post-Acute COVID-19 Care

Jennifer Possick M.D.

Associate Professor, Section of Pulmonary, Critical Care and Sleep Medicine

Yale University School of Medicine

Medical Director, Winchester Chest Clinic


Yale-New Haven Hospital



## Objectives


- Review post-COVID-19 respiratory symptoms and potential sequelae
- Explain how experience with other diseases informed our approach to post-COVID-19 pulmonary assessment
- Share our initial framework for providing post-COVID-19 evaluation in a pulmonary specialty clinic
- Discuss how initial observations are shaping the next steps in our approach

### A typical patient:




- 50-year-old man admitted in May with hypoxemic respiratory failure requiring high flow nasal cannula and prolonged hospitalization followed by short term rehab
- Initial pulmonary function tests showed severe restriction and diffusion impairment, though now off oxygen
- Follow up compute tomography chest shows clearance of infiltrates with minimal fibrosis
- Ongoing dyspnea and fatigue limiting return to work and hobbies
- · Lapses in memory and concentration, increased anxiety and depression

# Post-COVID-19 symptoms are common and diverse, with respiratory symptoms a frequent feature:




# In addition to persistent symptoms, the potential for persistent interstitial lung disease:




- Subset of patients with residual pulmonary infiltrates and fibrotic lung disease
- Correlates with deficits in pulmonary function (restriction, diffusion impairment)
- Associated with a signature of sustained inflammation through acute/postacute phase
- Risk factors incompletely understood but associated with age, male gender, and underlying comorbidities


### Patterns emerging:



# Pulmonary recovery from COVID-19 must be framed in a multidimensional context over a long time period:



## A familiar constellation of challenges in a COVID-19 context:



#### Our initial clinical model:

#### RECOVERY: CompREhensive Post-COVID CentER at Yale

#### Referral Pathway

#### Inpatients (pre-discharge)

#### Respiratory Assessment

- · Ambulatory oximetry
- Pulse oximeter & incentive spirometry training

#### **Functional Assessment**

- Physical & occupational therapy evaluation
- · Swallow evaluation

#### Care Coordination

- · Arrange home services
- · Address care barriers

#### Outpatients (ongoing sx)

 Referral by outpatient provider, occupational medicine provider, health system COVID-19 hotline, or self

#### **Initial Assessment**

#### Visit 1 (telehealth)

- · Pulmonary consultation
- · Subjective sx assessment
- Assess for extrapulmonary complications

#### **Initial Diagnostics**

- Repeat imaging (HRCT)
- PFTs, 6MWT
- Repeat selected labs

#### Visit 2 (face-to-face)

- Ongoing pumonary care
- PT/OT assessment
- · Subjective sx assessment
- Neurocognitive screening
- · Mental health screening
- Additional subspecialty involvement

#### **Subsequent Care**

#### MD visits

- Planned 3, 6, and 12 mo or as needed per severity
- Extrapulmonary consultation as needed

#### Rehab

- PT/OT outpatient care
- Pulmonary rehabilitation

#### Lung function testing

- PFT & 6MWT at 3, 6, 12 mo
- CPET for selected patients

#### Additional diagnostics

- VQ or CTA chest
- Transthoracic Echo
- · Cardiac event monitoring
- · Functional cardiac imaging
- · Neurocognitive testing

#### Disposition

#### Sx resolve & PFT normal

· Transition to primary care

#### Sx persist or PFT abnormal

- Non-specific phenotype → continue RECOVERY clinic
- Phenotype consistent with specific disease process → appropriate advanced lung disease program (e.g. interstitial lung disease, airways disease, pulmonary vascular disease)

Multi-disciplinary discussion of active cases

Translational research efforts

Revision of clinic processes to meet patient needs and evolving evidence

#### Observations for our next iteration:


- Imaging most helpful in those with abnormal PFTs or previously extensive abnormalities
- Partnership with PT has been essential, but what is the ideal rehab structure for this population?
- Social work heavily utilized and very effective
- Neurocognitive sequelae have been common
- "Subjective/objective mismatch" is common, optimal diagnostic pathway uncertain
- Most people slowly improving therefore supportive interventions may be more high value than serial diagnostics

### Thank you

- CDC
- Yale School of Medicine, Dept of Internal Medicine, and Section of Pulmonary, Critical Care and Sleep Medicine
- Yale-New Haven Hospital
- Winchester Chest Clinic Post-COVID-19 Recovery Program team
- Collaborators across YSM/YNHH and at other institutions

## Disclaimer

The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC).





cdc.gov/coronavirus

# Post-COVID Neurological Symptoms: Experiences From Our Center

Allison Navis, MD

Division Neuro-Infectious Diseases
Icahn School of Medicine at Mount
Sinai



#### **A COVID Timeline**

- April 2020: redeployed to serve as a medicine attending on an inpatient COVID service
- May 2020: neurology consult attending
  - COVID encephalopathy, strokes, acute disseminated encephalomyelitis (ADEM), Guillain-Barre Syndrome
- ▶ June 2020: started at the Center for Post-COVID Care at Mount Sinai Hospital
  - Expected: patients who had been hospitalized with moderate-severe COVID
  - Reality:
    - Neurology is top referral, along with pulmonology and cardiology
    - Majority of patients were not hospitalized
    - Wide range of neurological and non-neurological symptoms

- ▶ Concern for widespread neurological process?
  - ACE2 not widely expressed in brain but is expressed on vasculature
  - Case reports of COVID in brains on autopsy, but inflammatory damage greater
  - Is COVID more neurotropic than we expected?
- ▶ Neurological syndromes with objective deficits (e.g., mononeuropathy, brachial plexopathy) are occurring, but less common, and being referred to outside neurologists

<sup>\*</sup>ACE2 (angiotensin-converting enzyme 2) is the functional receptor providing SARS-CoV-2 entry into human cells

## **Example Post-COVID Patient**

- 42-year-old woman, no medical history, had COVID in April. Was sick for 2 weeks with fever, myalgias, headache and anosmia. Not hospitalized.
- Was feeling better but then noted in June she was having trouble with short-term memory and focus. Works at a nonprofit, continuing to work but has cut hours and struggles.
- Also notes physical fatigue that worsens with exercise. Gets tingling sensation throughout her body but worst in hands. Also with heart rate elevations, palpitations, and shortness of breath.

## **Neurological Symptoms--Brain Fog**

- Most common neurological symptom
- ▶ Issues with short-term memory, concentration and word-finding/speech difficulty
- ▶ No clear correlation with severity of COVID infection, age or comorbidities
- Symptoms often fluctuate, "good and bad days"
  - Fluctuations often correlate with other symptoms like fatigue and dysautonomia
- Impact on life varies: some able to still work, others on disability
- ► Sleep: many patients with poor sleep
- ▶ Mood: many patients experiencing depression, anxiety and/or PTSD

## Approach to workup

- ► Initially, broad workup undertaken
- ▶ Bloodwork for contributing, reversible causes
- Neuroimaging
- Neuropsychological testing
- ▶ EEG if concern for seizures
- ► EMG/nerve conduction studies for paresthesias
- ► Rare instances, lumbar puncture

## Neurological Symptoms--Headaches, Paresthesias and Dysautonomia

#### ▶ Headaches

- Often describes as constant pressure that can fluctuate in severity
- May have migraine symptoms or not
- Many don't have a history of headaches

#### Paresthesias

- Tingling, numbness and/or burning sensation
- May be focal, diffuse, alternating in locations
- Sometimes more in distal extremities (stocking-glove distribution)

#### Dysautonomia

- Fluctuating blood pressure and heart rate
- Lightheadedness, palpitations, GI disturbances


Most patients have multiple chief complaints. Rare to have someone coming in for only one issue


## Approach to workup: typical findings


- ► Initially, broad workup undertaken
- ▶ Bloodwork for contributing, reversible causes
- ▶ Neuroimaging- no widespread signs of damage from infection or inflammation
- ▶ Neuropsychological testing- variable
- ▶ EEG if concern for seizures- seizures do not appear to be a common complication
- ► EMG for paresthesias- negative for neuropathy in vast majority
- ► Rare instances, lumbar puncture- no major inflammatory/infectious changes

## **Neuroimaging: typical findings**

- ▶ Not seeing large inflammatory/infectious appearing lesions
- ▶ Not seeing many strokes, including lacunar strokes
- ▶ White matter changes (i.e., microvascular ischemic changes)
  - Very common imaging finding regardless of COVID
  - Occurs with age, vascular risk factors, migraines
  - Unless severe, often not considered clinically relevant
  - Caution in attributing to COVID without comparison imaging, or, if more severe than expected for age







## **Cognitive test: typical findings**

- ➤ Younger patients: results more often within normal limits
  - May be some decrease from presumed prior level of function
  - May show more issues with attention
- ▶ Older adults: deficits in varying domains
  - No clear pattern, or "post-COVID cognitive profile"
  - COVID unmasking underlying cognitive impairment versus causing
- Reports often comment on mood (depression, anxiety, PTSD), sleep and fatigue as potential contributing factors
- ▶ Brain Fog ≠ Dementia for most people
  - Does not mean cognitive changes are not present and interfering with life

# What else may be occurring? Our evolving understanding

## What may be occurring?

- Damage to central nervous system (CNS)?
  - Lack of evidence to support/refute
  - Unlikely widespread CNS infection. Role of vasculature?
- Peripheral nervous system may be affected
  - Much more vulnerable to systemic insults than central nervous system.
  - Presence of small fiber neuropathy?
  - Small fiber neuropathy leading to dysautonomia?
- Other, possibilities:
  - Postural orthostatic tachycardia syndrome (POTS)
    - Hyperadrenergic POTS relating to excessive catecholamines?
  - Myalgic encephalomyelitis/chronic fatigue syndrome (MECFS) like process?

- Small fiber neuropathy
  - Paresthesias
  - Dysautonomia/autonomic neuropathy
  - Chronic pain syndromes
  - Fatigue?

#### ▶ POTS

- Dysautonomia (orthostasis and tachycardia)
- Headaches
- Fatigue/ generalized weakness
- Paresthesias
- Brain fog

#### ▶ MECFS

- Overwhelming fatigue, not improved by rest
- Post-exertional malaise
- Associated with orthostatic intolerance, pain, poor sleep and brain fog

# **Current Approach to Workup and Management**

## **History**

- Symptoms and their correlation
  - If multiple symptoms, do they fit with a larger diagnosis?
- Severity of COVID
  - Associated complications, cytokine storm, hypoxia
- Age and medical comorbidities of patient
- Impact of symptoms on ability to work and/or activities of daily living
- ► FOCAL neurological deficits or symptoms
- ▶ Sleep
- Mood

## Workup--often aimed to look for contributing factors

- Bloodwork
  - TSH, Vitamin B12 and Vitamin D
  - HIV, RPR, thiamine, folate (if severe cognitive deterioration)
  - Hemoglobin A1c if neuropathy
- ► Imaging- MRI Brain (or CT Head)

Consider Imaging:	Can Consider Holding Imaging:
<ul> <li>Moderate-Severe COVID</li> <li>Over 50 years of age</li> <li>Medical comorbidities/risk factors</li> <li>Impact on job or iADLs</li> <li>Focal neurological deficits or symptoms</li> </ul>	<ul> <li>Not hospitalized/no complications with COVID</li> <li>Less than 50 years of age</li> <li>Otherwise healthy</li> <li>Correlation with other symptoms, has "good days"</li> </ul>

- Neuropsychological Testing
  - Can be helpful in highlighting if/what deficits present as well as potential contributing factors

## Workup

- ▶ EEG: if episodes of altered consciousness, seizure-like activity
- Lumbar puncture: only in cases of severe cognitive deterioration or other concerning neurological deficits.
- ► EMG: for neuropathy. Normal in small fiber neuropathy
- Skin biopsy for small fiber neuropathy- confirms diagnosis. Doesn't change management
- Autonomic function/tilt table testing- if concern for POTS

Likely okay to do a small, focused workup. Extensive testing has not been helpful in vast majority of patients.

## **Treatment: mostly symptomatic and supportive**

#### ▶ Brain fog:

- No specific treatment
- Address any abnormalities in bloodwork
- Address contributing factors
- If attention is major issue:
   Atomoxetine,
   dextroamphetamine/amphetamine,
   methylphenidate, modafinil

## Dysautonomia:

- Hydration, increase salt intake, compression stockings
- Meditation, breathwork
- POTS: consider adding in midodrine or fludrocortisone
- Hyperadrenergic POTS: betablocker

## Small fiber neuropathy:

- Address any abnormalities in bloodwork
- Symptomatic treatment of paresthesias: gabapentin, pregabalin, tricyclics, duloxetine
- Dysautonomia as above

## ► Fatigue:

- Treat associated symptoms as above
- Pacing of exercise: low-impact, short duration exercise with gradual increase. <u>Do not push</u> to recondition quickly

## Other critical factors

## ▶ Sleep:

- Sleep hygiene
- Assess for possible sleep apnea
- Sleep aids: melatonin, mirtazapine, gabapentin or amitriptyline (if paresthesias or headaches also present)

#### Mental Health:

- Critical to address while not being dismissive
- May be "the result of", not the primary cause of symptoms.
- Depression, anxiety and PTSD can affect cognition
- Something we can act on
- Anti-depressants like duloxetine or venlafaxine may be beneficial in also treating paresthesias and/or headaches

## Conclusion

- Many neurological symptoms present in post-COVID patients
- Many symptoms may correlate, important to get broad history
- ▶ So far, diagnostic workup is not providing much information
  - Likely okay to do less testing, unless red-flag symptoms present
  - Important to not over-interpret things like imaging
- Treatment is supportive and symptomatic
  - We don't have medications to "cure" neurological damage
- ▶ Multi-disciplinary approach with post-COVID experience is critical
- ▶ We don't know what is causing symptoms, but that does not mean this is not real.
- Reassurance. Patients can/do get better.

## To Ask a Question

- Using the Zoom Webinar System
  - Click on the "Q&A" button.
  - Type your question in the "Q&A" box.
  - Submit your question.
- For media questions, please contact CDC Media Relations at 404-639-3286 or email media@cdc.gov.

# **Continuing Education**

All continuing education for COCA Calls is issued online through the CDC Training & Continuing Education Online system at <a href="https://tceols.cdc.gov/">https://tceols.cdc.gov/</a>

Those who participate in today's COCA Call and wish to receive continuing education please complete the online evaluation by March 1, 2021, with the course code WC2922-012821. The access code is COCA012821. Those who will participate in the on-demand activity and wish to receive continuing education should complete the online evaluation between March 2, 2021 and March 2, 2023 and use course code WD2922-012821. The access code is COCA012821.

Continuing education certificates can be printed immediately upon completion of your online evaluation. A cumulative transcript of all CDC/ATSDR CEs obtained through the CDC Training & Continuing Education Online System will be maintained for each user.

# Today's COCA Call Will Be Available On-Demand

When: A few hours after the live call

What: Video recording

 Where: On the COCA Call webpage at <a href="https://emergency.cdc.gov/coca/calls/2021/callinfo">https://emergency.cdc.gov/coca/calls/2021/callinfo</a> 012821.asp

## **Upcoming COCA Calls**

- Visit our COCA Call page at <u>emergency.cdc.gov/coca</u>.
- Subscribe to receive notifications about upcoming COCA calls at emergency.cdc.gov/coca/subscribe.asp.
- Share call announcements with colleagues.

## **COCA Products & Services**



CDC Clinician Outreach and Communication Activity

COCA Call Announcements contain all information subscribers need to participate in COCA Calls. COCA Calls are held as needed.





Monthly newsletter that provides information on CDC training opportunities, conference and training resources, the COCA Partner Spotlight, and the Clinician Corner.



As-needed messages that provide specific, immediate action clinicians should take. Contains comprehensive CDC guidance so clinicians can easily follow recommended actions.

## **COCA Products & Services**







Monthly newsletter providing updates on emergency preparedness and response topics, emerging public health threat literature, resources for health professionals, and additional information important during public health emergencies and disasters.

Informs clinicians of new CDC resources and guidance related to emergency preparedness and response. This email is sent as soon as possible after CDC publishes new content.

CDC's primary method of sharing information about urgent public health incidents with public information officers; federal, state, territorial, and local public health practitioners; clinicians; and public health laboratories.

## Join COCA's Mailing List

#### Receive information about:

- Upcoming COCA Calls
- Health Alert Network (HAN) messages
- CDC emergency response activations
- Emerging public health threats
- Emergency preparedness and response conferences
- Training opportunities



emergency.cdc.gov/coca/subscribe.asp

## Join Us On Facebook!





# Thank you for joining us today!



emergency.cdc.gov/coca